OVARIAN CANCER METASTATIC

This adverse event was reported 850 times

OVARIAN CANCER METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 RELACORILANT 3 0.0303
1 ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE 4 0.0108
2 ESTERIFIED ESTROGENS, METHYLTESTOSTERONE 4 0.0108
3 BELINOSTAT 3 0.0084
4 MIRVETUXIMAB SORAVTANSINE 12 0.0066
5 PENICILLAMINE 6 0.0065
6 ILOPROST 6 0.0064
7 CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE 100 0.0043
8 TRABECTEDIN 9 0.0038
9 NIRAPARIB 70 0.0032
See all drugs enriched for association with OVARIAN CANCER METASTATIC

OVARIAN CANCER METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Prostacycline [EPC] 6 0.0064
1 Poly(ADP-Ribose) Polymerase Inhibitor [EPC] 37 0.0017
2 Estrogen [EPC] 182 0.0010
3 Guanylate Cyclase-C Agonist [EPC] 2 0.0010
4 Calcitonin [EPC] 3 0.0010
5 Histone Deacetylase Inhibitor [EPC] 3 0.0008
6 Vascular Endothelial Growth Factor Inhibitor [EPC] 121 0.0007
7 Provitamin D2 Compound [EPC] 19 0.0006
8 Microtubule Inhibitor [EPC] 89 0.0005
9 Platinum-based Drug [EPC] 113 0.0004
See all drug classes enriched for association with OVARIAN CANCER METASTATIC